New York State Common Retirement Fund Raises Stock Holdings in MiMedx Group, Inc (NASDAQ:MDXG)

New York State Common Retirement Fund boosted its holdings in MiMedx Group, Inc (NASDAQ:MDXG) by 51.8% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 87,781 shares of the company’s stock after purchasing an additional 29,941 shares during the period. New York State Common Retirement Fund owned about 0.06% of MiMedx Group worth $667,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MDXG. Virtus Fund Advisers LLC purchased a new position in MiMedx Group in the fourth quarter valued at about $35,000. Tower Research Capital LLC TRC boosted its holdings in MiMedx Group by 77.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company’s stock valued at $63,000 after purchasing an additional 2,837 shares during the last quarter. Cibc World Markets Corp purchased a new position in MiMedx Group in the fourth quarter valued at about $107,000. Ameriprise Financial Inc. purchased a new position in MiMedx Group in the fourth quarter valued at about $115,000. Finally, Sowell Financial Services LLC purchased a new position in MiMedx Group in the first quarter valued at about $115,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.

MiMedx Group Trading Down 1.2%

NASDAQ:MDXG opened at $6.77 on Friday. The company has a quick ratio of 4.13, a current ratio of 4.70 and a debt-to-equity ratio of 0.09. The business’s 50 day moving average is $6.45 and its two-hundred day moving average is $7.33. MiMedx Group, Inc has a 52 week low of $5.47 and a 52 week high of $10.14. The company has a market cap of $999.93 million, a PE ratio of 25.07 and a beta of 1.76.

MiMedx Group (NASDAQ:MDXG) last released its earnings results on Wednesday, April 30th. The company reported $0.06 EPS for the quarter, hitting analysts’ consensus estimates of $0.06. MiMedx Group had a return on equity of 22.70% and a net margin of 11.40%. The company had revenue of $88.21 million for the quarter, compared to the consensus estimate of $86.32 million. On average, analysts predict that MiMedx Group, Inc will post 0.3 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on MDXG shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $11.00 target price on shares of MiMedx Group in a report on Tuesday, July 15th. Wall Street Zen downgraded MiMedx Group from a “buy” rating to a “hold” rating in a report on Friday, July 18th.

Insider Buying and Selling at MiMedx Group

In related news, CEO Joseph H. Capper purchased 200,000 shares of the company’s stock in a transaction dated Friday, May 2nd. The shares were acquired at an average cost of $6.34 per share, for a total transaction of $1,268,000.00. Following the transaction, the chief executive officer owned 529,530 shares of the company’s stock, valued at $3,357,220.20. This trade represents a 60.69% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.70% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.